Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 421 to 431 of 431 entries
Sorted by: Best Match Show Resources per page
Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies.

Journal of biomolecular structure & dynamics

Sajid Jamal QM, Alharbi AH, Ahmad V.
PMID: 33826483
J Biomol Struct Dyn. 2021 Apr 07;1-15. doi: 10.1080/07391102.2021.1905551. Epub 2021 Apr 07.

After one year, the COVID-19 pandemic caused by SARS-CoV-2 is still the largest concern for the scientific community. Of the many recognized drug targets of SARS-CoV-2, the main protease is one of the most important target due to its...

Cite
Sajid Jamal QM, Alharbi AH, Ahmad V. Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies. J Biomol Struct Dyn. 2021;1-15doi: 10.1080/07391102.2021.1905551.
Sajid Jamal, Q. M., Alharbi, A. H., & Ahmad, V. (2021). Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies. Journal of biomolecular structure & dynamics, 1-15. https://doi.org/10.1080/07391102.2021.1905551
Sajid Jamal, Qazi Mohammad, et al. "Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies." Journal of biomolecular structure & dynamics vol. (2021): 1-15. doi: https://doi.org/10.1080/07391102.2021.1905551
Sajid Jamal QM, Alharbi AH, Ahmad V. Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies. J Biomol Struct Dyn. 2021 Apr 07;1-15. doi: 10.1080/07391102.2021.1905551. Epub 2021 Apr 07. PMID: 33826483; PMCID: PMC8043163.
Copy Download .nbib Format: NLM
Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Puvvadi R, Mikkelsen H, McCahon L, Grogan S, Ditcham W, Reid DW, Lamont I, Stick SM, Clements B.
PMID: 33341406
J Cyst Fibros. 2021 Mar;20(2):316-323. doi: 10.1016/j.jcf.2020.12.004. Epub 2020 Dec 16.

BACKGROUND: We tested if disrupting iron utilisation by P. aeruginosa by adding the Tris-buffered chelating agent CaEDTA to nebulised tobramycin would enhance bacterial clearance and improve lung function in CF patients.METHODS: In this double-blind, randomised controlled trial, 26 episodes...

Cite
Puvvadi R, Mikkelsen H, McCahon L, et al. Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial. J Cyst Fibros. 2020;20(2):316-323doi: 10.1016/j.jcf.2020.12.004.
Puvvadi, R., Mikkelsen, H., McCahon, L., Grogan, S., Ditcham, W., Reid, D. W., Lamont, I., Stick, S. M., & Clements, B. (2021). Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 20(2), 316-323. https://doi.org/10.1016/j.jcf.2020.12.004
Puvvadi, Ramaa, et al. "Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial." Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society vol. 20,2 (2021): 316-323. doi: https://doi.org/10.1016/j.jcf.2020.12.004
Puvvadi R, Mikkelsen H, McCahon L, Grogan S, Ditcham W, Reid DW, Lamont I, Stick SM, Clements B. Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial. J Cyst Fibros. 2021 Mar;20(2):316-323. doi: 10.1016/j.jcf.2020.12.004. Epub 2020 Dec 16. PMID: 33341406.
Copy Download .nbib Format: NLM
Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?.

Antibiotics (Basel, Switzerland)

Duong A, Simard C, Wang YL, Williamson D, Marsot A.
PMID: 33946905
Antibiotics (Basel). 2021 Apr 29;10(5). doi: 10.3390/antibiotics10050507.

BACKGROUND: Although aminoglycosides are often used as treatment for Gram-negative infections, optimal dosing regimens remain unclear, especially in ICU patients. This is due to a large between- and within-subject variability in the aminoglycoside pharmacokinetics in this population.OBJECTIVE: This review...

Cite
Duong A, Simard C, Wang YL, et al. Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?. Antibiotics (Basel). 2021;10(5)doi: 10.3390/antibiotics10050507.
Duong, A., Simard, C., Wang, Y. L., Williamson, D., & Marsot, A. (2021). Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?. Antibiotics (Basel, Switzerland), 10(5), . https://doi.org/10.3390/antibiotics10050507
Duong, Alexandre, et al. "Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?." Antibiotics (Basel, Switzerland) vol. 10,5 (2021). doi: https://doi.org/10.3390/antibiotics10050507
Duong A, Simard C, Wang YL, Williamson D, Marsot A. Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?. Antibiotics (Basel). 2021 Apr 29;10(5). doi: 10.3390/antibiotics10050507. PMID: 33946905; PMCID: PMC8145041.
Copy Download .nbib Format: NLM
Sleeping ribosomes: Bacterial signaling triggers RaiA mediated persistence to aminoglycosides.

iScience

Lang M, Krin E, Korlowski C, Sismeiro O, Varet H, Coppée JY, Mazel D, Baharoglu Z.
PMID: 34611612
iScience. 2021 Sep 14;24(10):103128. doi: 10.1016/j.isci.2021.103128. eCollection 2021 Oct 22.

Indole is a molecule proposed to be involved in bacterial signaling. We find that indole secretion is induced by sublethal tobramycin concentrations and increases persistence to aminoglycosides in

Cite
Lang M, Krin E, Korlowski C, et al. Sleeping ribosomes: Bacterial signaling triggers RaiA mediated persistence to aminoglycosides. iScience. 2021;24(10):103128doi: 10.1016/j.isci.2021.103128.
Lang, M., Krin, E., Korlowski, C., Sismeiro, O., Varet, H., Coppée, J. Y., Mazel, D., & Baharoglu, Z. (2021). Sleeping ribosomes: Bacterial signaling triggers RaiA mediated persistence to aminoglycosides. iScience, 24(10), 103128. https://doi.org/10.1016/j.isci.2021.103128
Lang, Manon, et al. "Sleeping ribosomes: Bacterial signaling triggers RaiA mediated persistence to aminoglycosides." iScience vol. 24,10 (2021): 103128. doi: https://doi.org/10.1016/j.isci.2021.103128
Lang M, Krin E, Korlowski C, Sismeiro O, Varet H, Coppée JY, Mazel D, Baharoglu Z. Sleeping ribosomes: Bacterial signaling triggers RaiA mediated persistence to aminoglycosides. iScience. 2021 Sep 14;24(10):103128. doi: 10.1016/j.isci.2021.103128. eCollection 2021 Oct 22. PMID: 34611612; PMCID: PMC8476650.
Copy Download .nbib Format: NLM
Emergence of Pseudomonas aeruginosa cross-infection in children with cystic fibrosis attending an Iranian referral pediatric center.

Iranian journal of microbiology

Ghazi M, Khanbabaee G, Fallah F, Kazemi B, Mahmoudi S, Navidnia M, Pourakbari B, Bakhshi B, Goudarzi H.
PMID: 23066486
Iran J Microbiol. 2012 Sep;4(3):124-9.

BACKGROUND AND OBJECTIVES: This study was carried out with the objective of determining the genomic variability of P. aeruginosa strains isolated from patients suffering from cystic fibrosis or from environmental cultures collected from different locations in the unit they...

Cite
Ghazi M, Khanbabaee G, Fallah F, et al. Emergence of Pseudomonas aeruginosa cross-infection in children with cystic fibrosis attending an Iranian referral pediatric center. Iran J Microbiol. 2012;4(3):124-9
Ghazi, M., Khanbabaee, G., Fallah, F., Kazemi, B., Mahmoudi, S., Navidnia, M., Pourakbari, B., Bakhshi, B., & Goudarzi, H. (2012). Emergence of Pseudomonas aeruginosa cross-infection in children with cystic fibrosis attending an Iranian referral pediatric center. Iranian journal of microbiology, 4(3), 124-9.
Ghazi, M, et al. "Emergence of Pseudomonas aeruginosa cross-infection in children with cystic fibrosis attending an Iranian referral pediatric center." Iranian journal of microbiology vol. 4,3 (2012): 124-9.
Ghazi M, Khanbabaee G, Fallah F, Kazemi B, Mahmoudi S, Navidnia M, Pourakbari B, Bakhshi B, Goudarzi H. Emergence of Pseudomonas aeruginosa cross-infection in children with cystic fibrosis attending an Iranian referral pediatric center. Iran J Microbiol. 2012 Sep;4(3):124-9. PMID: 23066486; PMCID: PMC3465537.
Copy Download .nbib Format: NLM
Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session (ESRD Study).

Canadian journal of kidney health and disease

Giroux M, Bouchard N, Henderson A, Lam L, Tran VAS, Projean D, Tessier JF, Lepage L, Gavra P, Ouellet G, Vallée M, Lafrance JP.
PMID: 33680482
Can J Kidney Health Dis. 2021 Feb 19;8:2054358120987061. doi: 10.1177/2054358120987061. eCollection 2021.

BACKGROUND AND OBJECTIVES: There is a renewed interest in the successful use of aminoglycosides due to increasing resistance in gram-negative infections. Few studies to date have examined the pharmacokinetics (PK) of intradialytic infusions of tobramycin. This study sought to...

Cite
Giroux M, Bouchard N, Henderson A, et al. Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session (ESRD Study). Can J Kidney Health Dis. 2021;8:2054358120987061doi: 10.1177/2054358120987061.
Giroux, M., Bouchard, N., Henderson, A., Lam, L., Tran, V. A. S., Projean, D., Tessier, J. F., Lepage, L., Gavra, P., Ouellet, G., Vallée, M., & Lafrance, J. P. (2021). Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session (ESRD Study). Canadian journal of kidney health and disease, 82054358120987061. https://doi.org/10.1177/2054358120987061
Giroux, Marjolaine, et al. "Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session (ESRD Study)." Canadian journal of kidney health and disease vol. 8 (2021): 2054358120987061. doi: https://doi.org/10.1177/2054358120987061
Giroux M, Bouchard N, Henderson A, Lam L, Tran VAS, Projean D, Tessier JF, Lepage L, Gavra P, Ouellet G, Vallée M, Lafrance JP. Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session (ESRD Study). Can J Kidney Health Dis. 2021 Feb 19;8:2054358120987061. doi: 10.1177/2054358120987061. eCollection 2021. PMID: 33680482; PMCID: PMC7897820.
Copy Download .nbib Format: NLM
Sensitive determination of tobramycin using homocystine capped gold nanoclusters as probe by second-order scattering.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

Chen X, Liu D, Wu H, Ji J, Xue Z, Feng S.
PMID: 35007909
Spectrochim Acta A Mol Biomol Spectrosc. 2022 Jan 03;270:120840. doi: 10.1016/j.saa.2021.120840. Epub 2022 Jan 03.

A novel photoluminescent Hcy-AuNCs has been developed through one-pot reduction method, to establish a tobramycin sensing by second-order scattering (SOS). Hcy-AuNCs could spontaneously assemble to small-scaled aggregation, resulting in remarkable intensity enhancement of scattered luminescence signals. The luminescence of...

Cite
Chen X, Liu D, Wu H, et al. Sensitive determination of tobramycin using homocystine capped gold nanoclusters as probe by second-order scattering. Spectrochim Acta A Mol Biomol Spectrosc. 2022;270:120840doi: 10.1016/j.saa.2021.120840.
Chen, X., Liu, D., Wu, H., Ji, J., Xue, Z., & Feng, S. (2022). Sensitive determination of tobramycin using homocystine capped gold nanoclusters as probe by second-order scattering. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 270120840. https://doi.org/10.1016/j.saa.2021.120840
Chen, Xinyue, et al. "Sensitive determination of tobramycin using homocystine capped gold nanoclusters as probe by second-order scattering." Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy vol. 270 (2022): 120840. doi: https://doi.org/10.1016/j.saa.2021.120840
Chen X, Liu D, Wu H, Ji J, Xue Z, Feng S. Sensitive determination of tobramycin using homocystine capped gold nanoclusters as probe by second-order scattering. Spectrochim Acta A Mol Biomol Spectrosc. 2022 Jan 03;270:120840. doi: 10.1016/j.saa.2021.120840. Epub 2022 Jan 03. PMID: 35007909.
Copy Download .nbib Format: NLM
Reduction in clinical response to empiric antimicrobial therapy of febrile granulocytopenic patients receiving TMP/SMX infection prophylaxis.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses

Bow EJ, Pater JL, Louie TJ, Feld R, Mandell L, Robson HG, Chow A, Belch A, Miedzinski L, Paul N, Elliott CR, Willan AR.
PMID: 22416197
Can J Infect Dis. 1992 Sep;3(5):235-9. doi: 10.1155/1992/286453.

In the course of a multicentre clinical trial evaluating two antibacterial regimens for the empiric treatment of suspected infection in febrile neutropenic cancer patients, a suboptimal response was noted among recipients of antibacterial prophylaxis with trimethoprim/sulphamethoxazole (TMP/SMX). Multivariate analysis...

Cite
Bow EJ, Pater JL, Louie TJ, et al. Reduction in clinical response to empiric antimicrobial therapy of febrile granulocytopenic patients receiving TMP/SMX infection prophylaxis. Can J Infect Dis. 1992;3(5):235-9doi: 10.1155/1992/286453.
Bow, E. J., Pater, J. L., Louie, T. J., Feld, R., Mandell, L., Robson, H. G., Chow, A., Belch, A., Miedzinski, L., Paul, N., Elliott, C. R., & Willan, A. R. (1992). Reduction in clinical response to empiric antimicrobial therapy of febrile granulocytopenic patients receiving TMP/SMX infection prophylaxis. The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses, 3(5), 235-9. https://doi.org/10.1155/1992/286453
Bow, E J, et al. "Reduction in clinical response to empiric antimicrobial therapy of febrile granulocytopenic patients receiving TMP/SMX infection prophylaxis." The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses vol. 3,5 (1992): 235-9. doi: https://doi.org/10.1155/1992/286453
Bow EJ, Pater JL, Louie TJ, Feld R, Mandell L, Robson HG, Chow A, Belch A, Miedzinski L, Paul N, Elliott CR, Willan AR. Reduction in clinical response to empiric antimicrobial therapy of febrile granulocytopenic patients receiving TMP/SMX infection prophylaxis. Can J Infect Dis. 1992 Sep;3(5):235-9. doi: 10.1155/1992/286453. PMID: 22416197; PMCID: PMC3298065.
Copy Download .nbib Format: NLM
Identification of a series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity.

JCI insight

Kenyon EJ, Kirkwood NK, Kitcher SR, Goodyear RJ, Derudas M, Cantillon DM, Baxendale S, de la Vega de León A, Mahieu VN, Osgood RT, Wilson CD, Bull JC, Waddell SJ, Whitfield TT, Ward SE, Kros CJ, Richardson GP.
PMID: 33735112
JCI Insight. 2021 Apr 08;6(7). doi: 10.1172/jci.insight.145704.

To identify small molecules that shield mammalian sensory hair cells from the ototoxic side effects of aminoglycoside antibiotics, 10,240 compounds were initially screened in zebrafish larvae, selecting for those that protected lateral-line hair cells against neomycin and gentamicin. When...

Cite
Kenyon EJ, Kirkwood NK, Kitcher SR, et al. Identification of a series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity. JCI Insight. 2021;6(7)doi: 10.1172/jci.insight.145704.
Kenyon, E. J., Kirkwood, N. K., Kitcher, S. R., Goodyear, R. J., Derudas, M., Cantillon, D. M., Baxendale, S., de la Vega de León, A., Mahieu, V. N., Osgood, R. T., Wilson, C. D., Bull, J. C., Waddell, S. J., Whitfield, T. T., Ward, S. E., Kros, C. J., & Richardson, G. P. (2021). Identification of a series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity. JCI insight, 6(7), . https://doi.org/10.1172/jci.insight.145704
Kenyon, Emma J, et al. "Identification of a series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity." JCI insight vol. 6,7 (2021). doi: https://doi.org/10.1172/jci.insight.145704
Kenyon EJ, Kirkwood NK, Kitcher SR, Goodyear RJ, Derudas M, Cantillon DM, Baxendale S, de la Vega de León A, Mahieu VN, Osgood RT, Wilson CD, Bull JC, Waddell SJ, Whitfield TT, Ward SE, Kros CJ, Richardson GP. Identification of a series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity. JCI Insight. 2021 Apr 08;6(7). doi: 10.1172/jci.insight.145704. PMID: 33735112; PMCID: PMC8133782.
Copy Download .nbib Format: NLM
Tobramycin-loaded complexes to prevent and disrupt Pseudomonas aeruginosa biofilms.

Drug delivery and translational research

Boffoli D, Bellato F, Avancini G, Gurnani P, Yilmaz G, Romero M, Robertson S, Moret F, Sandrelli F, Caliceti P, Salmaso S, Cámara M, Mantovani G, Mastrotto F.
PMID: 34841492
Drug Deliv Transl Res. 2021 Nov 28; doi: 10.1007/s13346-021-01085-3. Epub 2021 Nov 28.

Carbohydrate-based materials are increasingly investigated for a range of applications spanning from healthcare to advanced functional materials. Synthetic glycopolymers are particularly attractive as they possess low toxicity and immunogenicity and can be used as multivalent ligands to target sugar-binding...

Cite
Boffoli D, Bellato F, Avancini G, et al. Tobramycin-loaded complexes to prevent and disrupt Pseudomonas aeruginosa biofilms. Drug Deliv Transl Res. 2021;doi: 10.1007/s13346-021-01085-3.
Boffoli, D., Bellato, F., Avancini, G., Gurnani, P., Yilmaz, G., Romero, M., Robertson, S., Moret, F., Sandrelli, F., Caliceti, P., Salmaso, S., Cámara, M., Mantovani, G., & Mastrotto, F. (2021). Tobramycin-loaded complexes to prevent and disrupt Pseudomonas aeruginosa biofilms. Drug delivery and translational research, . https://doi.org/10.1007/s13346-021-01085-3
Boffoli, Delia, et al. "Tobramycin-loaded complexes to prevent and disrupt Pseudomonas aeruginosa biofilms." Drug delivery and translational research vol. (2021). doi: https://doi.org/10.1007/s13346-021-01085-3
Boffoli D, Bellato F, Avancini G, Gurnani P, Yilmaz G, Romero M, Robertson S, Moret F, Sandrelli F, Caliceti P, Salmaso S, Cámara M, Mantovani G, Mastrotto F. Tobramycin-loaded complexes to prevent and disrupt Pseudomonas aeruginosa biofilms. Drug Deliv Transl Res. 2021 Nov 28; doi: 10.1007/s13346-021-01085-3. Epub 2021 Nov 28. PMID: 34841492.
Copy Download .nbib Format: NLM
New Biodegradable Drug Delivery System for Patients with Dry Eye.

Korean journal of ophthalmology : KJO

Park BC, Kim HT, Koh JW.
PMID: 34488255
Korean J Ophthalmol. 2021 Dec;35(6):455-459. doi: 10.3341/kjo.2021.0126. Epub 2021 Sep 06.

PURPOSE: This study aimed to develop a new type of drug delivery system (DDS) for treatment of dry eye.METHODS: A new lens-type biodegradable DDS was manufactured using gelatin methacryloly, antibiotics, and conjunctival epithelial cells as bio-inks in a Bio...

Cite
Park BC, Kim HT, Koh JW. New Biodegradable Drug Delivery System for Patients with Dry Eye. Korean J Ophthalmol. 2021;35(6):455-459doi: 10.3341/kjo.2021.0126.
Park, B. C., Kim, H. T., & Koh, J. W. (2021). New Biodegradable Drug Delivery System for Patients with Dry Eye. Korean journal of ophthalmology : KJO, 35(6), 455-459. https://doi.org/10.3341/kjo.2021.0126
Park, Beom Chan, et al. "New Biodegradable Drug Delivery System for Patients with Dry Eye." Korean journal of ophthalmology : KJO vol. 35,6 (2021): 455-459. doi: https://doi.org/10.3341/kjo.2021.0126
Park BC, Kim HT, Koh JW. New Biodegradable Drug Delivery System for Patients with Dry Eye. Korean J Ophthalmol. 2021 Dec;35(6):455-459. doi: 10.3341/kjo.2021.0126. Epub 2021 Sep 06. PMID: 34488255.
Copy Download .nbib Format: NLM
Showing 421 to 431 of 431 entries